HYDERABAD, India--(BUSINESS WIRE)--Dr. Reddy’s Laboratories (NYSE:RDY) today announced that it has entered into an agreement with SkyePharma PLC (LSE:SKP) to undertake a feasibility study of a product utilizing two of SkyePharma’s proprietary drug delivery systems. The costs of this study will be paid by Dr. Reddy’s. SkyePharma will also receive an upfront payment. If the feasibility study is successful, full development activities will begin later this year.
